Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 24, 2019

View Archived Issues

More microbes between heaven and earth

Ammonia scavenger prevents tox at the source

Dormancy, resistance are separate issues in metastasis prevention

Funding supports further phase I development of Minervax's group B Streptococcus vaccine

HIF-2alpha inhibitor reverses pulmonary vascular remodeling, inhibits RHF, promotes survival in PAH

Novel selective tankyrase inhibitor blocks proliferation of colorectal cancer cells in rodent models

KZR-616, a dual immunoproteasome subunit inhibitor for autoimmune diseases

Bermekimab demonstrates efficacy in confirmatory study in patients with hidradenitis suppurativa

First patient enrolled in phase II study of SGM-1019 for the treatment of NASH

Athersys announces positive results from exploratory study of MultiStem cell therapy in ARDS

PeptiDream announces new BBB-penetrating PDC discovery deal with Shionogi

Phase IIb study of centanafadine sustained release in adults with ADHD meets primary endpoint

Phase II data presented for andecaliximab plus nivolumab in gastric cancer

Genentech and NewLink Genetics patent IDO and TDO inhibitors

Durvalumab and tremelimumab plus chemotherapy show promising safety in patients with ESCC

Medshine Discovery synthesizes new IRAK-4 inhibitors

[18F]RO-948 PET differentiates Alzheimer's disease from other neurodegenerative conditions

NantBioScience discloses new BACE1 inhibitors

The Vanderbilt University identifies metabotropic mGlu4 receptor PAMs

Sarepta initiates open-label extension study of SRP-5051 in Duchenne muscular dystrophy

Recordati Industria Chimica e Farmaceutica divulges mGlu5 receptor PAMs

CAMP4 Therapeutics announces rare disease research collaboration with Alnylam

New phase II trial explores use of huCART19 in very high-risk subsets of pediatric B-ALL

Basilea and Roche will collaborate to study derazantinib with atezolizumab in urothelial cancer

Ironwood begins first-in-human study of CNS-penetrant sGC stimulator IW-6463

FDA places partial clinical hold on phase III study of axalimogene filolisbac in cervical cancer